Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03112603||Recruiting||A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)||
||324||All||12 Years and older (Child, Adult, Older Adult)||NCT03112603||INCB 18424-365 (REACH3)
|June 23, 2017||July 2019||January 2022||April 13, 2017||June 15, 2018||